Stage 1 embryonal rhabdomyosarcoma of the female genital tract: a retrospective clinical study of nine cases

Table 1 Stage, treatment, and prognosis of embryonal rhabdomyosarcoma of the female genital tract

No.	Age (years)	Tumor site	The longest tumor diameter (cm)	Stage (FIGO)	Stage (IRSG)	IRSG group	IRSG risk stratification	Primary treatment	Treatment for recurrence	Status at last follow-up	Survival time^a (month)
1	17	Vagina	1.0	I	1	I	Low, subset A	S	C	Dead	25.0
2	6	Vagina	4.9	I	1	III	Low, subset B	C	S+C	NED	117.0
3	34	Vagina	6.0	II	1	I	Low, subset A	S	N	NED	15.0
4	36	Cervix	5.7	IIIA	1	I	Low, subset A	NC+S+C	N	NED	9.0
5	20	Cervix	12.0	IIA2	1	I	Low, subset A	S+C	N	NED	153.0
6	37	Cervix	2.0	IB1	1	I	Low, subset A	S+C^b	P	Dead	14.0
7	21	Cervix	0.5	IB1	1	I	Low, subset A	S+C	N	NED	151.0
8	21	Cervix	10.5	IIA2	1	I	Low, subset A	S+C	N	NED	228.0
9	23	Cervix	4.5	IB2	1	I	Low, subset A	S+C+R	N	NED	198.0

IRSG Intergroup Rhabdomyosarcom Study Group, S surgery, C chemotherapy, NC neoadjuvant chemotherapy, R radiotherapy, P palliative treatment, N without recurrence, NED no evidence of disease
^aThe cutoff date of the follow-up was April 1, 2015
^bOnly received two courses of chemotehrapy

ISSN: 1477-7819